Detailed Opportunity Analysis
High-Probability Biotech Setups – April 2026 🚀 High-Probability Biotech Setups Week of April 13–17, 2026 Catalyst-driven trades built for momentum and asymmetric upside. Strategy: • Small sizing (1–2%) • Enter near support • Cut losers fast • Scale winners into strength 📊 Catalyst Overview TVTX – Travere Therapeutics PDUFA decision (FSGS kidney disease) 65–75% probability View Chart IDYA – Ideaya Biosciences Phase 2/3 melanoma data 50–65% View Chart MGTX – MeiraGTx Gene therapy durability data 70–85% View Chart ASMB – Assembly Biosciences HSV-2 clinical data (Gilead partner) 75–90% View Chart KURA – Kura Oncology Oncology combo data update 60–75% View Chart 🧬 Why These Matter TVTX: Rare kidney disease company. Approval = immediate revenue shift. IDYA: Precision oncology. Biomarker targeting increases success odds. MGTX: Gene therapy platform. Strong durability potential. ASMB: Backed by Gilead. Large unme...